Phase 1 Imaging Study of 89Zr-DFO-HuMab-5B1 With HuMab-5B1
Status:
Terminated
Trial end date:
2017-05-05
Target enrollment:
Participant gender:
Summary
Open label, nonrandomized, dose-escalation trial of MVT-2163 and MVT-5873 used in performing
PET scans. The study is designed to determine the best time and dose of these agents that
result in the best PET image of a tumor. Subjects will be seen on days 1, 2, 4, and 7 for
imaging and a clinical assessment. The last study visit is on day 28.
Phase:
Phase 1
Details
Lead Sponsor:
BioNTech Research & Development, Inc. MabVax Therapeutics, Inc.